Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 0.85 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.85 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.85 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.85 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.85 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.85 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.85 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444203 | 0.93 | MTOR (0.74) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL20765097 | 0.93 | MTOR (1.00) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL32393 | 0.93 | MTOR (1.00) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL2442221 | 0.92 | MTOR (0.73) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL20765154 | 0.91 | MTOR (0.93) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL32727 | 0.90 | MTOR (0.95) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL32828 | 0.89 | MTOR (0.93) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL20765101 | 0.89 | MTOR (0.88) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| SCHEMBL32433 | 0.88 | MTOR (0.91) | MTORPIK3CAPIK3CGPIK3CBPIK3CD | |
| Gedatolisib SCHEMBL29047454 | 0.88 | MTOR (0.90) | MTORPIK3CAPIK3CGPIK3CBPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040934-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2013-02-14 | — | — | US | claimed |
| EP-2547684-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | University of Basel (CH) | 2013-01-23 | — | — | EP | claimed |
| WO-2011114275-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-09-22 | — | — | WO | claimed |
| US-20130040934-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040934-A1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | CDK4, GRK4, RPS6KA4 | MTOR 6/4885PIK3CA 13/4885PIK3CG 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.